What concept plate does Yong Technology belong to? Yongtai science and technology concept plate analysis; 1. Lithium battery: mainly engaged in pharmaceutical intermediates business; 2065438+September 2007, the new phase of the "Annual Output of 3,000 Tons of Lithium Hexafluoride Phosphoric Acid Project" of Yonggaotao Subsidiary was put into production, and it has started to deliver goods to major customers at home and abroad. 2. Children's Medical Care: It was announced in April 2006, 2065438 that the company planned to purchase 0/00% equity of Zhejiang Palm/Kloc with a fixed cash, and 90% equity of Foshan Palm with a total price of 700 million yuan. In addition, the company plans to increase matching funds by 700 million yuan. The above-mentioned fixed issue price and reserve price are both 19.57 yuan/share. The output of methyldopa and gabapentin, the characteristic raw material drugs of Zhejiang Palm, ranks first in the country; Foshan palm products cover digestive system drugs, antibiotics, cardiovascular drugs, children's drugs and other fields. Last year, Zhejiang Palm achieved a net profit of 36 1.8 million yuan, while Foshan Palm also turned losses into profits, with a net profit of 26.5438+0.45 million yuan. 3. Fluorite: The company is the leading enterprise of fluorobenzene series fine chemicals with the most complete product chain and the largest production capacity in the industry. Fine chemicals sub-industry is at the high end of fluorine chemical industry, and it is the sub-industry with the highest added value and the largest product sales in the whole fluorine chemical industry. 4. Organic light-emitting diodes: The company's CF photoresist products can be applied to the production and manufacture of organic light-emitting diode products, breaking the overseas monopoly, and the construction project of organic light-emitting diode electronic materials with an annual output of 60 tons is under construction. 5. Asthma: The company holds 65,438+05% equity of Shanghai Aibisen Pharmaceutical Co., Ltd. Recently, the chewable tablets and ordinary tablets of montelukast declared by Anbixin were approved by the State Medical and Drug Administration, becoming the first similar drug to pass the consistency evaluation of generic drugs. Therefore, Ambixin became the first drug research and development institution in China to hold a drug listing license. Montelukast sodium is a leukotriene receptor antagonist, which is used to treat and prevent asthma in children and adults, and also to treat allergic rhinitis. 6. Chinese medicine: On April 20, 2020, the company said on the interactive platform that Yongtai Palm has an annual output of 4,340 tons of Chinese medicine raw materials and 600 million Chinese medicine pills. The first phase of the project is currently undergoing equipment installation and commissioning. 7. Conformity evaluation of generic drugs: Montelukast chewable tablets and ordinary tablets declared by Shanghai Aibisen, a shareholding company, were approved by the State Pharmaceutical Product Supervision and Administration, becoming the first similar drug to pass the conformity evaluation of generic drugs. Therefore, Shanghai Abbison became the first drug research and development institution with drug marketing license in China. 8. Standard & Poor's Dow Jones A shares: 20 18 12 1. The index compiling company Standard & Poor's Dow Jones announced that some China A shares will be included in its global index system and basically classified as emerging markets. September 20 19, s&; P Dow Jones Emerging Markets Index is included in A shares with an inclusion factor of 25%. 9. Organic light-emitting diode materials: The company's CF photoresist products can be applied to the production and manufacture of organic light-emitting diode products, breaking the overseas monopoly. An annual output of 60 tons of organic light-emitting diode electronic materials construction project is under construction. 10. Biomedicine: It was announced on April 20 16 that the company plans to purchase 0/00% equity of Zhejiang Palm and 90% equity of Foshan Palm, with a total price of 700 million yuan. In addition, the company plans to increase matching funds by 700 million yuan. The above-mentioned fixed issue price and reserve price are both 19.57 yuan/share. The output of methyldopa and gabapentin, the characteristic raw material drugs of Zhejiang Palm, ranks first in the country; Foshan palm products cover digestive system drugs, antibiotics, cardiovascular drugs, children's drugs and other fields. Last year, Zhejiang Palm achieved a net profit of 36 1.8 million yuan, while Foshan Palm also turned losses into profits, with a net profit of 26.5438+0.45 million yuan. 1 1. new material concept: the company is one of the most complete and productive manufacturers of fluorine fine chemicals in China. Fluorine fine chemicals industry is located at the top of fluorine chemical industry chain, with high added value and wide application range, involving liquid crystal materials, medicine, pesticides and so on. In terms of fluorine-containing liquid crystal chemicals, the company's main products are 3,5-difluorobenzene, 3,4,5-trifluorobromobenzene, 3,4,5-trifluorophenol and 2,3,4-trifluoroaniline, which rank first in the country. In medicine and chemical industry, the sales volume of the company's main product, 2,3,4-trifluoronitrobenzene, ranks first in the country; In terms of pesticide chemicals, the sales of the company's main products, 3,5-difluoroaniline and 2,4-difluorobenzene, rank first in China. 12. photoresist: electronic chemicals: annual output of Yongtai new materials1500t CF photoresist project has entered the project acceptance stage. The company's annual output of 60 tons of organic light-emitting diode electronic materials construction project has been steadily advanced, and the layout in the field of flat panel display has continued to increase.